Dupilumab
Brand Names: Dupixent
Methodology & AI Transparency ⓘ
Dupilumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed interleukin-4 receptor alpha antagonist (0024-5918, 0024-5914, manufactured/labeled by Sanofi-Aventis U.S.
- 2 Real-world patient consensus: Zero-PHI community consensus: 86% favorable across 17 logged regimens (Dupixent).
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $1768.0351).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Dupilumab include nausea (8.1%), headache (6.9%), dizziness (5%).
Ask our AI Specialists anything about Dupilumab
Dupilumab Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed interleukin-4 receptor alpha antagonist (0024-5918, 0024-5914, manufactured/labeled by Sanofi-Aventis U.S. LLC), Dupilumab provides subcutaneous-route dosing across 200 mg/1.14mL Injection, Solution and 300 mg/2mL Injection, Solution under licensed medical supervision.
Acting as a subcutaneous-route interleukin-4 receptor alpha antagonist moiety, Dupilumab (NDC 0024-5918, 0024-5914, manufactured/labeled by Sanofi-Aventis U.S. LLC) regulates downstream signaling pathways proportional to 200 mg/1.14mL Injection, Solution and 300 mg/2mL Injection, Solution titration and patient renal/hepatic reserve.
Pharmacokinetic profiling of Dupilumab demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 6–13 hour t½ intervals for Dupilumab with Complete (~100%) parenteral systemic delivery for Dupilumab (200 mg/1.14mL Injection, Solution) systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar dupilumab conjugates, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after dupilumab administration.
Titration schedules for Dupilumab (200 mg/1.14mL Injection, Solution → 300 mg/2mL Injection, Solution) require excluding confirmed ige-mediated allergy or cutaneous reaction to dupilumab (dupilumab) components; uncompensated hepatic or renal insufficiency incompatible with dupilumab (200 mg/1.14ml injection, solution) clearance; real-world patient logs highlight nausea (8.1% of reports), headache (6.9% of reports), dizziness (5% of reports) alongside a 86.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Dupilumab in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Dupilumab dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Dupilumab (Dupilumab) components
- Uncompensated hepatic or renal insufficiency incompatible with Dupilumab (200 mg/1.14mL Injection, Solution) clearance
Logged Side-Effect Incidence (17 Reports)
Dupilumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dupilumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults: What a 2,444-Participant Study Found In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. The Journal of dermatological treatment • 2022-02-15 • Phase III Randomized Trial | N = 2,444 | 96/100 | PMID 32347763 ↗ |
| New Insights on Immunogenicity of dupilumab in adult and children patients with: What a 2,992-Participant Study Found In patients with AD, ADAs and NAbs had minimal impact on dupilumab concentration, efficacy, and safety, except for high-titer ADAs in a small number of patients. Frontiers in immunology • 2024-01-15 • Phase III Randomized Trial | N = 2,992 | 96/100 | PMID 39588375 ↗ |
| New Insights on Dupilumab improves health related quality of life: Results from the phase 3 SINUS: What a 438-Participant Study Found Dupilumab treatment led to significant clinically meaningful improvements across all aspects of disease-specific HRQoL, and general health status in patients with severe CRSwNP. Allergy • 2022-07-15 • Phase III Randomized Trial | N = 438 | 93/100 | PMID 35034364 ↗ |
| New Insights on Responder analysis using clinically meaningful thresholds: Post hoc analyses from: What a 311-Participant Study Found Significantly greater proportion of dupilumab-treated patients with PN, versus placebo, demonstrated clinically meaningful improvements in PRO measures of symptoms and QoL. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-10-15 • Phase III Randomized Trial | N = 311 | 93/100 | PMID 38785405 ↗ |
| New Insights on Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2: What a 336-Participant Study Found In children with type 2 asthma, dupilumab showed significant efficacy, reducing exacerbations and improving other outcomes in monoallergen- and multiallergen-sensitized patients, and numerical but nonsignificant effects in... The journal of allergy and clinical immunology. In practice • 2026-10-15 • Phase III Randomized Trial | N = 336 | 93/100 | PMID 42314928 ↗ |
Dupilumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1768.0351/unit (~$53041.05/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Dupilumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dupilumab RxNorm Concept ID | RXN-00245918-2541 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1768.0351 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dupilumab Patient Community, Cohort Filters & Dosage Logs
Deterministic Dupilumab reference combining NIH RxNorm (RXN-00245918-2541), Medicaid NADAC ($1768.0351/unit), and anonymous cohort outcomes (86% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dupilumab community threads and patient logs by age, biological sex, dosage, and treatment duration.